- Drug Pipelines
- January 2024
- 60 Pages
Global
From €1454EUR$1,500USD£1,245GBP
- Report
- February 2024
- 78 Pages
Global
From €3500EUR$3,869USD£3,103GBP
- Report
- July 2022
- 57 Pages
Global
From €3392EUR$3,500USD£2,905GBP
- Drug Pipelines
- October 2020
- 60 Pages
Global
From €3392EUR$3,500USD£2,905GBP
- Report
- November 2021
- 600 Pages
Global
From €3876EUR$4,000USD£3,320GBP
The Nociceptin Receptor is a G-protein coupled receptor that is involved in the modulation of pain. It is a target for the development of analgesic drugs, which are used to treat pain. Analgesics that target the Nociceptin Receptor are thought to be more effective than traditional analgesics, as they are able to target the source of the pain more precisely. This has led to the development of a number of Nociceptin Receptor-targeting drugs, such as Naloxone, Naltrexone, and Naloxegol. These drugs are used to treat a variety of pain conditions, including chronic pain, neuropathic pain, and cancer pain.
The Nociceptin Receptor market is an emerging market, with a number of companies developing drugs to target the receptor. These companies include AstraZeneca, Merck, Pfizer, and Johnson & Johnson. Show Less Read more
